ERVW-1 and interstitial lung disease: Our SIV-based LV platform, pseudotyped with F and HN envelope proteins of Sendai virus, is being developed for the treatment of interstitial lung diseases (ILDs), as well as conducting airway disorders (e.g., cystic fibrosis), and has been shown to efficiently transduce murine lungs and human ALI cell models based on human bronchial epithelial cells.9